RV-01

N/A

Report date: 2026/03/28 20:00:32
First In Class

Base Information

Drug NameRV-01
Drug Alias Name177 Lu-BetaBart177Lutetium-conjugated B7-H3 radioantibodyLu177-B7H3-mAbRV-01177Lu-RV01
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantUterine Cervical Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRadiopharm Ventures
China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm VenturesRadiopharm Theranostics Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantUterine Cervical Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A